IVF parents are spending thousands to predict their babies’ chances of having Alzheimer’s, cancer and heart disease

Maybe she’s born with it, maybe it’s … genetic optimization?

Prospective parents using in vitro fertilization (IVF) will soon be able to select embryos based on their potential risk for diseases — including illnesses that develop later in life — thanks to a groundbreaking $5,999 service announced this week by a US biotech company.

“Before there’s a heartbeat, there’s DNA,” Kian Sadeghi, founder and chief executive of Nucleus Genomics, said in a statement. “One file containing DNA and genetic markers can tell you more about your baby’s future than any other test a doctor could possibly run at this stage.”

What is IVF? 

The popular fertility treatment involves removing eggs from a woman’s ovaries and fertilizing them with sperm in a lab.

The resulting embryo — which could be frozen or fresh — is placed into the uterus, where it hopefully implants in the uterine wall and sparks a pregnancy.

Before implantation, many IVF clinics already screen embryos for genetic abnormalities — such as extra chromosomes or gene mutations — that can lead to failed implantations, miscarriages, birth defects or inherited disorders.

But the first-of-its-kind service from Nucleus Genomics takes things a step further. 

Build-a-baby

The company just launched Nucleus Embryo, a new software platform that lets potential parents dig deep into the full genetic blueprint of their embryos before choosing which one to implant.

The tool lets IVF patients compare the DNA of up to 20 embryos, screening them for more than 900 conditions — including Alzheimer’s, Type 2 diabetes, heart disease and several forms of cancer.

It doesn’t stop there.

The program also flags potential mental health conditions like depression and schizophrenia and even ranks cognitive traits like IQ. 

Parents can also get a look at cosmetic and physical features, from height, baldness and BMI to eye and hair color.

The company isn’t promising perfection.

Instead, the software generates a so-called polygenic risk score that will give parents the probability of how likely it is an embryo might develop certain traits or diseases.

Ultimately, it’s up to the parents to decide which qualities matter most to them. For those looking to decode the results, genetic counseling sessions are available.

“Lifespan has dramatically increased in the last 150 years,” Sadeghi told the Wall Street Journal. “DNA testing to predict and reduce chronic disease can make it happen again.”

A new era of reproductive tech

The practice, known as polygenic embryo screening, is already highly controversial in the medical world, according to a report published by Harvard Law School’s Petrie-Flom Center.

Critics warn that allowing parents to screen embryos for risks like depression or diabetes could deepen stigma and discrimination against people living with those conditions.

Meanwhile, disability advocates argue it promotes the harmful idea that disability is something to be fixed, not a natural part of human diversity.

And when it comes to choosing embryos for traits like intelligence or athleticism, critics say we’re sliding into designer baby territory — a modern form of eugenics that favors the rich, reinforcing social and healthcare inequalities.

Still, the public appears open to some aspects of the tech.

A 2023 survey found that 77% of Americans support using it to screen embryos for the likelihood of developing certain physical conditions, while 72% back screening for mental health risks.

Proponents argue it’s no different from vaccination — a preventive tool, not a judgment on those with the condition.

But when it comes to non-medical traits, support drops fast: only 36% back screening embryos for behavioral traits and just 30% for physical features like height or eye color.